ImClone Systems Corporation · New York, NY United States
| 180 Varick St. | Phone: 212-645-1405 |
| New York, NY | Fax: 212-645-2054 |
| 10014 | |
| United States |
Map This Company |
- Company Profiles
- Competitive Landscapes
- Industry Reports
Buy Reports
For a Hoover's Free Trial, Call
(866) 444-8642or
Chat NowImClone Systems Corporation Rankings
Company Description
ImClone Systems wants to create identically successful cancer drug candidates. The company, a subsidiary of Eli Lilly, is focused on the development of oncology-related antibody therapies. The biotech research firm's only commercial product, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb (BMS) in North America and with Merck KGaA elsewhere. The company is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. It also has other potential oncology treatments in development.

ImClone Systems Corporation Reports

No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.

Financials
| Company Type | SubsidiaryHeadquarters |
|---|
| Fiscal Year-End | December |
|---|
| Employees | 1,128 |
|---|
Top ImClone Systems Corporation Competitors